Galmed announces positive results from first 16 patients in open-label part of armor study

Tel aviv, israel, nov. 1, 2021 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results from the first 16 patients in the open-label part of the armor phase 3 study who underwent a scheduled post-baseline biopsy.
GLMD Ratings Summary
GLMD Quant Ranking